Federal cannabis policy, product safety and media consolidation lead today’s news. A bipartisan employment bill could reduce the consequences of past marijuana use, while a Maine contamination advisory underscores continuing quality-control risks and California officials negotiate over a transformative Hollywood merger.
Bipartisan Bill Targets Cannabis Barriers to Federal Employment
Representatives Jamie Raskin, a Maryland Democrat, and Zachary Nunn, an Iowa Republican, introduced the Cannabis Users’ Restoration of Eligibility Act, or CURE Act, on September 17. The legislation would prevent federal agencies from using past marijuana use by itself to deny a security clearance or determine that an applicant is unsuitable for federal employment.
H.R. 10504 would also establish a process for reviewing certain employment and clearance denials dating back to January 1, 2008. The measure has been referred to the House Committee on Oversight and Government Reform and must still advance through Congress before it can become law.
Why It Matters: The bill addresses a practical conflict between widespread state legalization and federal hiring standards. Analysis: Even without broader legalization, changing clearance rules could expand the talent pool available to intelligence, cybersecurity, defense and other agencies competing for specialized workers.
Source: Marijuana Moment
Maine Warns Patients About Butane in Cannabis Concentrate
Maine’s Office of Cannabis Policy issued an advisory concerning “Deep Sea” cannabis concentrate sold by Ganja World, a medical cannabis delivery service in central Maine. Regulators began investigating after two patients reported adverse health reactions.
Testing of two samples detected 7,970 and 10,500 parts per million of butane, compared with the state adult-use program’s 5,000-parts-per-million pass-fail threshold. The product was sold in 14-gram jars, and officials warned that inhaling concentrate with unsafe butane levels may cause respiratory irritation, headaches, hoarseness and nose or throat pain.
Why It Matters: Concentrates can create significant safety and liability exposure when extraction solvents remain above acceptable levels. Analysis: The incident may increase scrutiny of testing, manufacturing controls and product traceability within medical cannabis supply chains.
Source: Maine Office of Cannabis Policy
Paramount and California Make Progress in Warner Bros. Settlement Talks
Paramount Skydance and California Attorney General Rob Bonta have made progress in negotiations that could resolve the California-led antitrust challenge to Paramount’s proposed takeover of Warner Bros. Discovery, according to reports citing people familiar with the discussions. California and 11 other states have sued to block the transaction.
No agreement has been announced, and the scope of any concessions remains unsettled. The negotiations carry additional urgency because Paramount faces higher financial obligations if the deal remains incomplete after September 30.
Why It Matters: A settlement could clear a major obstacle to combining Paramount, Warner Bros., CBS, CNN, HBO and other major entertainment properties. Analysis: The outcome could reshape streaming competition, theatrical distribution, cable-channel ownership and the future concentration of production jobs in Los Angeles.
Source: Los Angeles Times
What We’re Watching
Over the next 24 to 72 hours, watch for a formal Paramount settlement or new merger concessions, additional sponsors or committee activity for the CURE Act, and any expansion of Maine’s cannabis advisory into enforcement action, additional testing or a broader product withdrawal.
